Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel Consortium (Consortium). The Consortium announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive scientific opinion for arpraziquantel to treat one of the neglected tropical diseases, schistosomiasis, in preschool-aged chi
Merck set to host Bilharzia Storytelling Lab in Kenya
Shares
Merck has announced a plan to host its first Bilharzia Storytelling Lab in Kenya. The lab is a three-day workshop bringing together 30 Kenyan community leaders and storytellers. The participants will be working on the task to develop new innovative ways of storytelling to empower and inform risk groups on prevention and or treatment of bilharzia.
More than 240 million people worldwide require treatment for the Neglected Tropical Disease (NTDs) bilharzia (also known as schistosomiasis or snail fever). It is estimated that 200,000 people die from the consequences of their long-term infections each year.